Global advances and future directions in lung cancer care: expert consensus and strategic priorities. (2026-02) Meyer, M-L ; Peters, S ; Jänne, P A ; Mok, T S ; Bunn, P A ; Abdel Karim, N ; Altorki, N K ; Arrieta, O ; Bar, J ; Cappuzzo, F ; Carbone, D ; Dacic, S ; Diehn, M ; Dziadziuszko, R ; Felip, E ; Flores, R ; Florez, N ; Forde, P M ; Gainor, J F ; Gray, J E ; Gros, L ; Halmos, B ; Henschke, C I ; Herbst, R ; Heymach, J V ; Kelly, K ; Kris, M G ; Leighl, N B ; Mathias, C ; Marron, T U ; Mulshine, J L ; Naidoo, J ; Osarogiagbon, R ; Passaro, A ; Peled, N ; Planchard, D ; Politi, K ; Popat, S ; Pyenson, B ; Reckamp, K L ; Ren, S H ; Riely, G J ; Rolfo, C ; Rudin, C M ; Sen, T ; Shields, M D ; Singh, H ; Skoulidis, F ; Solomon, B J ; Stahel, R ; Stiles, B M ; Syrigos, K ; CHIH-HSIN YANG ; PAN-CHYR YANG ; Wolf, A ; Wozniak, A J ; Waqar, S N ; Wakelee, H ; Hirsch, F R
Utility of various programmed death-ligand 1 (PD-L1) assays in predicting the clinical benefit of immune checkpoint inhibitors in PD-L1-expressing non-small-cell lung cancer patients: a systematic review. (2026-01-31) Soo, Ross A ; Lim, Darren Wan-Teck ; CHIH-HSIN YANG ; Herbst, Roy S ; JIN-YUAN SHIH
MAGELLAN arms B1 and B3: Durvalumab plus chemotherapy with and without oleclumab in treatment-naïve metastatic non-small-cell lung cancer. (2026-01) Cho, Byoung Chul ; Charoentum, Chaiyut ; Kim, Dong-Wan ; Yang, Cheng-Ta ; Dziadziuszko, Rafal ; Geater, Sarayut Lucien ; Mann, Helen ; Afshar-Imani, Banafsheh ; Lyfar, Pavlo ; CHIH-HSIN YANG ; Patel, Sandip Pravin
PD-L1 expression and immune profiling cannot predict osimertinib efficacy in lung cancer with EGFR T790 M mutation: A translational study. (2026) CHING-YAO YANG ; WEI-YU LIAO ; KUAN-YU CHEN ; CHAO-CHI HO ; TZU-HSIU TSAI ; CHIA-LIN HSU ; KANG-YI SU ; YIH-LEONG CHANG ; CHEN-TU WU ; Hsu, Chia-Chi ; Liu, Yi-Nan ; Peng, Guan-Ru ; Kangartaputra, Almanzo Aeterna ; SHU-HAN YU ; BIN-CHI LIAO ; Hsu, Wei-Hsun ; JIH-HSIANG LEE ; CHIA-CHI LIN ; JIN-YUAN SHIH ; CHIH-HSIN YANG ; CHONG-JEN YU
Savolitinib Plus Osimertinib in Epidermal Growth Factor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial. (2026-01) CHIH-HSIN YANG ; Chen, Yuh-Min ; Batra, Ullas ; Do, Kien Hung ; Sitthideatphaiboon, Piyada ; Danchaivijitr, Pongwut ; Lee, Kang-Yun ; Chindaprasirt, Jarin ; Yang, Cheng-Ta ; Chang, Gee-Chen ; Charoentum, Chaiyut ; Ungtrakul, Teerapat ; Moran, Juan Ignacio Hernandez ; Hartmaier, Ryan ; Igwegbe, Ike ; Gont, Alexander ; Haskins, Matthew ; Xu, Wanning ; Riess, Jonathan W
腫瘤免疫微環境特性及表皮生長因子受體突變非小細胞肺癌免疫抑制機制探索( I )=Characterization of Tumor Immune Microenvironment and Exploration of Immunosuppression Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer( I ) (2024-08-01~) CHIH-HSIN YANG
Expanding Caregiving Capacities for Caregivers of Older Adults with Newly Diagnosed Advanced Lung Cancer: a Study of Current Status and Evaluation of the "Integrating Nurse-Led and Resource Utilization-Based Caregiver Support Model (Icsm)" = 擴展新診斷晚期肺癌老年病人主要照顧者之照護能力及資源運用: 現況探討與測試"整合護理引導及資源使用之照護者支持模式" (2024-08-01~) YEUR-HUR LAI
國立臺灣大學高等教育深耕計畫-特色領域研究中心 【子計畫三_癌症】 (2023-01-02~) CHIH-HSIN YANG
Intrinsic Activities of Program Death Ligand 1 Promote Progression and Metastasis in Lung Cancer Cells (2022-08-01~) CHIH-HSIN YANG
Intrinsic Activities of Program Death Ligand 1 Promote Progression and Metastasis in Lung Cancer Cells (2021-08-01~) CHIH-HSIN YANG